Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.
暂无分享,去创建一个
I. Pastan | M. Brechbiel | K. Garmestani | O. Gansow | S. Kinuya | T. McMurry | L. Camera | C. Wu | L. Pai | C. Paik | T. Mcmurry
[1] B. Blazar,et al. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4. , 1991, Cancer research.
[2] S. Mirzadeh,et al. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. , 1990, Bioconjugate chemistry.
[3] M. Pykett,et al. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. , 1987, Cancer research.
[4] D. Hnatowich,et al. Generator-produced yttrium-90 for radioimmunotherapy. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] N. Cheung,et al. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. , 1986, Journal of the National Cancer Institute.
[6] P. Doherty,et al. DTPA-coupled antibodies labeled with yttrium-90. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] B. Wessels,et al. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. , 1984, Medical physics.